Dr. Ingmar Gorman is a psychologist who specializes in helping people who use psychedelics and other psychoactive compounds. He received his clinical training at the New School for Social Research, Mount Sinai Beth Israel Hospital, Columbia University, and Bellevue Hospital. He completed his NIH postdoctoral fellowship at New York University in 2017. Dr. Gorman was formerly the Director of the Psychedelic Education and Continuing Care Program at the Center for Optimal Living and is now the co-founder of Fluence, a psychedelic education company training mental health providers in psychedelic treatments. Along with Dr. Paleos, he is currently site co-principal investigator and therapist on a Phase 3 clinical trial of MDMA-assisted Psychotherapy for Post-Traumatic Stress Disorder.Email
Dr. Alan K Davis is an Assistant Professor of Social Work at The Ohio State University and Adjunct Assistant Professor in the Center for Psychedelic and Consciousness Research at Johns Hopkins University. Dr. Davis’s clinical experience includes working with people diagnosed with trauma-based psychological problems such as addiction, PTSD, depression, and anxiety. His clinical expertise includes providing evidenced-based treatments such as motivational interviewing, cognitive behavioral therapy, acceptance and commitment therapy, and psilocybin-assisted psychotherapy. Consistent with his clinical interests, his research interests and expertise focus on contributing to the knowledge of and ability to help those suffering with substance use and mental health problems, understanding how to improve clinical outcomes through examining new treatments, and developing ways to conceptualize substance use and mental health problems through a strengths-based approach. He recently completed a clinical trial of psilocybin therapy for major depressive disorder and current trials include exploring this treatment for patients with co-occurring alcohol use disorder and depression and patients with anorexia. He actively explores topics related to naturalistic psychedelic use among several populations including people of color who have experienced racial trauma, Spanish-speaking people, and people who use novel psychedelics such as 5-MeO-DMT.Email
Kelly Sykes, PhD is a child forensic psychologist and maintains a private practice in Brooklyn, New York. She works primarily with court referred families as a custody evaluator, parenting or family coordinator, or therapeutic supervisor. She also provides expert consultation and testimony in matters that concern parent-child contact problems, child sexual abuse evaluations, trauma & parenting, and adoption & termination of parental rights. Her work is heavily influenced by psychoanalysis and attachment theory. Kelly’s interest in psychedelic integration therapy evolved from years of working with court-referred parents with histories of complex trauma, persistent mood disorders, and substance abuse problems. Noting that for some, talk therapies helped with insight but failed to inhibit endangering behavior or led to meaningful change such that they could parent their children. This sparked her interest in learning more about the role the brain plays in the chronicity of certain psychological conditions and the research on psychedelic treatments.
Aja Molinar is a graduate student in psychology at the New School for Social Research, where she is a member of the Psychopathology Lab. Aja is also a member of the Portland Psychedelics Virtual Research Lab led by Dr. Jason Luoma and Dr. Brian Pilecki. She is interested in psychedelic science, in addition to research on boredom and depression. Within the Psychopathology Lab, she is also part of a team designing a protocol to measure clinical outcomes for ketamine-assisted psychotherapy. Aja has also assisted in writing a peer-reviewed article with Dr. Ingmar Gorman and Dr. Elizabeth Nielson on psychedelic harm reduction and integration.